World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
44
Citations
9723
World Ranking
19230
National Ranking
440

Daniel Podzamczer publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Daniel Podzamczer sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 212 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Daniel Podzamczer D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel Podzamczer sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 44 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Daniel Podzamczer is affiliated with Bellvitge University Hospital in Spain and has contributed extensively to medical research, particularly in the field of infectious diseases. Their research primarily addresses HIV/AIDS drug development, treatment, and related health complications.

The main fields of study covered by their work include:

  • Medicine
  • Immunology and Microbiology

Within these fields, the subfields of particular focus are:

  • Infectious Diseases
  • Virology
  • Emergency Medicine
  • Epidemiology
  • Oncology

The topics most frequently investigated by Daniel Podzamczer are:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV/AIDS Research and Interventions
  • Viral-associated cancers and disorders
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Lipoproteins and Cardiovascular Health

Their recent significant publications include:

  • Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials (2020), The Lancet HIV
  • Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study (2021), The Lancet HIV
  • Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study (2021), Open Forum Infectious Diseases
  • Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial (2021), The Lancet HIV
  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials (2020), UNC Libraries

Frequent co-authors collaborating with Daniel Podzamczer include:

  • Estebán Martínez
  • María Saumoy
  • Peré Domingo
  • Mar Masiá
  • Juan Tiraboschi

They have published in several journals and venues, notably:

  • Journal of Antimicrobial Chemotherapy
  • Open Forum Infectious Diseases
  • The Lancet HIV
  • SSRN Electronic Journal
  • Journal of Pharmaceutical and Biomedical Analysis

Best Publications

  • Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

    Francois Raffi;Anita Rachlis;Hans-Jürgen Stellbrink;W David Hardy

  • Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

    David A. Margolis;Juan Gonzalez-Garcia;Hans Jürgen Stellbrink;Joseph J. Eron

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.

    J. Berenguer;P. Ryan;J. Rodríguez-Baño;I. Jarrín

  • Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

    Frank A Post;Graeme J Moyle;Hans Jürgen Stellbrink;Pere Domingo

  • A prospective study of the risk of tuberculosis among HIV-infected patients.

    A Guelar;J M Gatell;J Verdejo;D Podzamczer

  • Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

    Sharon Walmsley;Axel Baumgarten;Juan Berenguer;Franco Felizarta

  • Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Jean-Michel Molina;Douglas Ward;Indira Brar;Anthony Mills

  • Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

    José R Arribas;Pierre-Marie Girard;Roland Landman;Judit Pich

  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

    Samir K. Gupta;Frank A. Post;José R. Arribas;Joseph J. Eron

  • Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

    Jing Yuan;Sheng Guo;David Hall;Anna M Cammett

  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

    Jean-Michel Molina;Kathleen Squires;Paul E Sax;Pedro Cahn

  • A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

    Margaret A. Johnson;Joseph C. Gathe;Daniel Podzamczer;Jean-Michel Molina

  • Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.

    Daniel Podzamczer;Albert Salazar;Josep Jimenez;Ezequiel Consiglio

  • Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

    Richard B. Pollard;Jürgen K. Rockstroh;Giuseppe Pantaleo;David M. Asmuth

  • Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.

    Luz Martin-Carbonero;Ana Barrios;Pere Saballs;Guillem Sirera

  • Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

    Vicente Soriano;Keikawus Arasteh;Horacio Migrone;Thomas Lutz

  • Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).

    Jesús Rodríguez-Baño;Jerónimo Pachón;Jordi Carratalà;Pablo Ryan

Frequent Co-Authors

Pere Domingo
Pere Domingo Autonomous University of Barcelona
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
Hernando Knobel
Hernando Knobel Autonomous University of Barcelona
Juan Berenguer
Juan Berenguer Hospital General Universitario Gregorio Marañón
José M. Gatell
José M. Gatell University of Barcelona
José M. Miró
José M. Miró University of Barcelona
Santiago Moreno
Santiago Moreno Hospital Universitario Ramón y Cajal
Chloe Orkin
Chloe Orkin Queen Mary University of London
Federico Pulido
Federico Pulido Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens the door to a wide array of advanced online degrees and career options in healthcare and science. Students can seamlessly extend their education into specialized graduate or professional programs to boost their employability and impact in growing fields.

Those interested in healthcare management may consider enrolling in the top online mha programs that are cahme accredited, which deliver industry-recognized credentials for future healthcare leaders. If you are seeking a clinical doctorate with more flexibility, look into a dnp program without clinical hours, designed for working professionals seeking leadership roles in nursing.

Ambitious students can also advance into online doctoral programs healthcare administration, combining scientific knowledge with executive skills for senior positions in the healthcare sector. Pharmacology enthusiasts may pursue online pharmd programs to transition into high-demand pharmacy roles without attending traditional campus classes.

These related online degrees support a wide variety of career pathways and are ideal for science graduates looking to deepen their expertise, specialize, or move into healthcare leadership and policy.

Best Scientists Citing Daniel Podzamczer

Trending Scientists

Recently Published Articles